NZ722122A - Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia - Google Patents

Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Info

Publication number: NZ722122A
Authority: NZ; New Zealand
Prior art keywords: crf1 receptor; receptor antagonists; methyl; adrenal hyperplasia; congenital adrenal
Prior art date: 2014-01-21

Application number

NZ722122A

Other languages

English (en)

Inventor

Dimitri Grigoriadis

Original Assignee

Neurocrine Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-21

Filing date

2015-01-21

Publication date

2020-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52450623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ722122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-21 Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc

2020-06-26 Publication of NZ722122A publication Critical patent/NZ722122A/en

Links

208000005676 Adrenogenital syndrome Diseases 0.000 title abstract 4
108091005471 CRHR1 Proteins 0.000 title abstract 4
208000008448 Congenital adrenal hyperplasia Diseases 0.000 title abstract 4
239000002464 receptor antagonist Substances 0.000 title abstract 4
229940044551 receptor antagonist Drugs 0.000 title abstract 4
VKHVAUKFLBBZFJ-SFHVURJKSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-[(1s)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N([C@@H](CC)C=1ON=C(C)N=1)C(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1C VKHVAUKFLBBZFJ-SFHVURJKSA-N 0.000 abstract 2
ANNRUWYFVIGKHA-UHFFFAOYSA-N 3-[6-(dimethylamino)-4-methylpyridin-3-yl]-2,5-dimethyl-n,n-dipropylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(N(CCC)CCC)=CC(C)=NC2=C1C1=CN=C(N(C)C)C=C1C ANNRUWYFVIGKHA-UHFFFAOYSA-N 0.000 abstract 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
IEAKXXNRGSLYTQ-DEOSSOPVSA-N SSR 125543 Chemical compound C1=C(C)C(OC)=CC(Cl)=C1C1=C(C)SC(N(CC#C)[C@@H](CC2CC2)C=2C=C(F)C(C)=CC=2)=N1 IEAKXXNRGSLYTQ-DEOSSOPVSA-N 0.000 abstract 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
229960000258 corticotropin Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NZ722122A 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia NZ722122A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461929941P	2014-01-21	2014-01-21
US201461981033P	2014-04-17	2014-04-17
US201462069155P	2014-10-27	2014-10-27
PCT/US2015/012315 WO2015112642A1 (en)	2014-01-21	2015-01-21	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Publications (1)

Publication Number	Publication Date
NZ722122A true NZ722122A (en)	2020-06-26

Family

ID=52450623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ722122A NZ722122A (en)	2014-01-21	2015-01-21	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Country Status (24)

Country	Link
US (5)	US20170020877A1 (2)
EP (2)	EP3096756B1 (2)
JP (5)	JP6585625B2 (2)
KR (2)	KR102258522B1 (2)
CN (2)	CN106102740A (2)
AU (4)	AU2015209452C1 (2)
BR (1)	BR112016016975B1 (2)
CA (2)	CA2936974A1 (2)
DK (1)	DK3096756T3 (2)
ES (1)	ES2984706T3 (2)
FI (1)	FI3096756T3 (2)
HR (1)	HRP20241046T1 (2)
HU (1)	HUE068315T2 (2)
IL (5)	IL304134B2 (2)
LT (1)	LT3096756T (2)
MX (3)	MX389004B (2)
NZ (1)	NZ722122A (2)
PL (1)	PL3096756T3 (2)
PT (1)	PT3096756T (2)
RS (1)	RS65839B1 (2)
RU (1)	RU2718918C2 (2)
SI (1)	SI3096756T1 (2)
SM (1)	SMT202400361T1 (2)
WO (1)	WO2015112642A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11951112B2 (en)	2021-04-12	2024-04-09	Maxim Masiutin	Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS65839B1 (sr) *	2014-01-21	2024-09-30	Neurocrine Biosciences Inc	Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
EP3107569A4 (en)	2014-02-20	2018-02-21	Alder Biopharmaceuticals, Inc.	Anti-acth antibodies and use thereof
JP7187037B2 (ja)	2016-09-07	2022-12-12	ザリージェンツオブザユニバーシティオブカリフォルニア	ｐ－タウを減少させ、認知機能を改善させるアロステリック副腎皮質刺激ホルモン放出因子受容体１（ＣＲＦＲ１）アンタゴニスト
WO2019036503A1 (en) *	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) *	2018-04-27	2026-01-14	Spruce Biosciences, Inc.	Methods for treating testicular and ovarian adrenal rest tumors
JP7532328B2 (ja) *	2018-12-07	2024-08-13	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20220023266A1 (en) *	2018-12-07	2022-01-27	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) *	2019-07-19	2022-09-26	スプルースバイオサイエンシーズ，インク．	先天性副腎過形成を処置する方法
JP7623365B2 (ja) *	2019-09-27	2025-01-28	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
CR20220624A (es) *	2020-06-10	2023-07-06	Sanofi Sa	Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
KR20240023691A (ko)	2020-08-12	2024-02-22	스프루스 바이오사이언시스 인코포레이티드	다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4949582B1 (2)	1969-01-20	1974-12-27
US4783443A (en)	1986-03-03	1988-11-08	The University Of Chicago	Amino acyl cephalosporin derivatives
FR2692893B1 (fr)	1992-06-24	1994-09-02	Sanofi Elf	Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en)	1996-02-07	2003-12-16	Neurocrine Biosciences, Inc.	Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6159980A (en)	1996-09-16	2000-12-12	Dupont Pharmaceuticals Company	Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr)	1996-10-08	1998-12-31	Sanofi Sa	Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DE69818248T2 (de)	1997-04-22	2004-06-17	Janssen Pharmaceutica N.V.	Chinolin- und chinazolin-derivate als crf antagonisten
WO1999010350A1 (en)	1997-08-22	1999-03-04	Du Pont Pharmaceuticals Company	NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
US6531475B1 (en)	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
CA2369553A1 (en)	1999-04-02	2000-10-12	Raymond F. Horvath	N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr)	1999-07-15	2001-08-17	Sanofi Synthelabo	Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr)	1999-12-17	2002-02-22	Sanofi Synthelabo	Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7276526B2 (en)	2001-07-13	2007-10-02	Bristol-Myers Squibb Pharma Company	Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2005079807A1 (en)	2004-02-13	2005-09-01	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
EP1781257B1 (en)	2004-08-13	2018-12-19	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7652035B2 (en)	2004-10-19	2010-01-26	Neurocrine Bioscience, Inc.	CRF receptor antagonists and methods relating thereto
EP1869049B1 (en)	2005-03-21	2009-03-04	Eli Lilly And Company	Imidazopyridazine compounds
US7557103B2 (en)	2005-04-05	2009-07-07	Eli Lilly And Company	Imidazopyridazine compounds
TWI370820B (en)	2005-04-27	2012-08-21	Takeda Pharmaceutical	Fused heterocyclic compounds
JPWO2006126718A1 (ja)	2005-05-27	2008-12-25	田辺三菱製薬株式会社	ピラゾロピリミジン誘導体
WO2007054719A2 (en)	2005-11-10	2007-05-18	Topotarget Uk Limited	Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007069565A1 (ja)	2005-12-12	2007-06-21	Ono Pharmaceutical Co., Ltd.	二環式複素環化合物
JPWO2007069671A1 (ja)	2005-12-15	2009-05-21	小野薬品工業株式会社	二環式複素環化合物
PL1982178T3 (pl)	2006-02-07	2014-02-28	Phenoquest Ag	Sposoby leczenia zaburzeń afektywnych
EP1834641A1 (en)	2006-03-16	2007-09-19	Sanofi-Aventis	Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
US20090306137A1 (en)	2006-05-22	2009-12-10	Wolfgang Curt D	Treatment for depressive disorders
HRP20100516T1 (hr)	2006-09-20	2010-10-31	Eli Lilly And Company	Tiazolpirazolopirimidini kao antagonisti receptora crf1
JP5184536B2 (ja)	2006-09-20	2013-04-17	イーライリリーアンドカンパニー	チオフェンピラゾロピリミジン化合物
US20100056515A1 (en)	2006-10-25	2010-03-04	Kazuyoshi Aso	Benzimidazole compounds
WO2008083070A1 (en)	2006-12-29	2008-07-10	Neurogen Corporation	Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
JP2010514672A (ja)	2006-12-29	2010-05-06	武田薬品工業株式会社	Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
TW200902019A (en)	2007-04-26	2009-01-16	Ono Pharmaceutical Co	Dicyclic heterocyclic compound
WO2009008552A1 (en)	2007-07-11	2009-01-15	Taisho Pharmaceutical Co., Ltd.	8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en)	2008-05-30	2009-12-03	Pfizer Limited	Novel compounds
US7932256B2 (en)	2008-07-31	2011-04-26	Bristol-Myers Squibb Company	(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
JP2011529899A (ja)	2008-07-31	2011-12-15	ブリストル−マイヤーズスクイブカンパニー	副腎皮質刺激ホルモン放出因子受容体活性のモジュレーターとしての置換カルバメート誘導体
US7994203B2 (en)	2008-08-06	2011-08-09	Novartis Ag	Organic compounds
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
JP5800428B2 (ja)	2008-11-03	2015-10-28	ジンテスゲゼルシャフトミットベシュレンクテルハフツング	調整式ロッド組立体
US8551996B2 (en)	2009-02-20	2013-10-08	Emory University	Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en)	2009-04-30	2011-03-28	Sanofi Aventis	Process for preparing of thiazole amines and intermediates thereof
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
EP2487177A1 (en)	2009-10-08	2012-08-15	Eisai R&D Management Co., Ltd.	Pyrazoloxazole compound
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja)	2010-02-01	2013-05-20	ノバルティスアーゲー	ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja)	2010-02-02	2015-07-15	ノバルティスアーゲー	Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
SG10201608579UA (en)	2012-04-13	2016-12-29	Epizyme Inc	Combination therapy for treating cancer
US20150278438A1 (en) *	2012-04-23	2015-10-01	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Genetic predictors of response to treatment with crhr1 antagonists
US20150094310A1 (en)	2012-04-23	2015-04-02	Holsboermaschmeyer Neurochemie Gmbh	Crhr1 antagonists for use in the treatment of patients having crh overactivity
RS65839B1 (sr) *	2014-01-21	2024-09-30	Neurocrine Biosciences Inc	Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
WO2016065177A1 (en)	2014-10-22	2016-04-28	The Trustees Of The University Of Pennsylvania	Method of treating depression and other stress related disorders
US9714246B2 (en)	2015-02-06	2017-07-25	Neurocrine Biosciences, Inc.	[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
EP3277836B1 (en)	2015-04-02	2019-02-27	HMNC Value GmbH	Method of treatment using genetic predictors of a response to treatment with ssr-125543
WO2018012066A1 (ja) *	2016-07-14	2018-01-18	株式会社コナミデジタルエンタテインメント	ゲームシステム、端末装置及びプログラム
EP3548035A4 (en)	2016-11-30	2020-07-22	Case Western Reserve University	COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
WO2018219804A1 (en)	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Self-microemulsifying drug delivery systems
JP7285222B2 (ja)	2017-08-14	2023-06-01	スプルースバイオサイエンシズインコーポレイテッド	副腎皮質刺激ホルモン放出因子受容体拮抗薬
WO2019036503A1 (en)	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en)	2018-04-27	2026-01-14	Spruce Biosciences, Inc.	Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en)	2018-12-07	2022-01-27	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja)	2019-07-19	2022-09-26	スプルースバイオサイエンシーズ，インク．	先天性副腎過形成を処置する方法
JP7623365B2 (ja)	2019-09-27	2025-01-28	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
TW202134241A (zh)	2019-12-04	2021-09-16	美商紐羅克里生物科學有限公司	Ｃｒｆ受體拮抗劑及使用方法
CR20220624A (es)	2020-06-10	2023-07-06	Sanofi Sa	Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
US20240024330A1 (en)	2020-08-26	2024-01-25	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use

2015
- 2015-01-21 RS RS20240910A patent/RS65839B1/sr unknown
- 2015-01-21 KR KR1020167022375A patent/KR102258522B1/ko active Active
- 2015-01-21 ES ES15702917T patent/ES2984706T3/es active Active
- 2015-01-21 PT PT157029174T patent/PT3096756T/pt unknown
- 2015-01-21 EP EP15702917.4A patent/EP3096756B1/en active Active
- 2015-01-21 LT LTEPPCT/US2015/012315T patent/LT3096756T/lt unknown
- 2015-01-21 RU RU2016133972A patent/RU2718918C2/ru active
- 2015-01-21 KR KR1020217015795A patent/KR20210064407A/ko not_active Ceased
- 2015-01-21 FI FIEP15702917.4T patent/FI3096756T3/fi active
- 2015-01-21 MX MX2016009499A patent/MX389004B/es unknown
- 2015-01-21 JP JP2016565135A patent/JP6585625B2/ja active Active
- 2015-01-21 BR BR112016016975-1A patent/BR112016016975B1/pt active IP Right Grant
- 2015-01-21 CA CA2936974A patent/CA2936974A1/en active Pending
- 2015-01-21 HR HRP20241046TT patent/HRP20241046T1/hr unknown
- 2015-01-21 IL IL304134A patent/IL304134B2/en unknown
- 2015-01-21 WO PCT/US2015/012315 patent/WO2015112642A1/en not_active Ceased
- 2015-01-21 EP EP24174933.2A patent/EP4450070A1/en active Pending
- 2015-01-21 NZ NZ722122A patent/NZ722122A/en unknown
- 2015-01-21 CN CN201580005270.4A patent/CN106102740A/zh active Pending
- 2015-01-21 IL IL317035A patent/IL317035A/en unknown
- 2015-01-21 CN CN202010134003.XA patent/CN111228274A/zh active Pending
- 2015-01-21 CA CA3155599A patent/CA3155599A1/en active Pending
- 2015-01-21 DK DK15702917.4T patent/DK3096756T3/da active
- 2015-01-21 US US15/113,362 patent/US20170020877A1/en not_active Abandoned
- 2015-01-21 HU HUE15702917A patent/HUE068315T2/hu unknown
- 2015-01-21 SM SM20240361T patent/SMT202400361T1/it unknown
- 2015-01-21 PL PL15702917.4T patent/PL3096756T3/pl unknown
- 2015-01-21 IL IL296683A patent/IL296683B2/en unknown
- 2015-01-21 AU AU2015209452A patent/AU2015209452C1/en active Active
- 2015-01-21 SI SI201532025T patent/SI3096756T1/sl unknown
2016
- 2016-07-14 IL IL246783A patent/IL246783B/en unknown
- 2016-07-21 MX MX2021012539A patent/MX2021012539A/es unknown
- 2016-07-21 MX MX2022000080A patent/MX2022000080A/es unknown
2018
- 2018-12-20 US US16/227,127 patent/US10905690B2/en active Active
2019
- 2019-03-11 JP JP2019043466A patent/JP6936825B2/ja active Active
2020
- 2020-06-09 JP JP2020099865A patent/JP7104743B2/ja active Active
- 2020-07-20 AU AU2020207774A patent/AU2020207774B2/en active Active
- 2020-10-20 US US17/074,845 patent/US11730739B2/en active Active
2021
- 2021-08-04 US US17/393,553 patent/US11311544B2/en active Active
- 2021-09-29 IL IL286782A patent/IL286782A/en unknown
- 2021-11-12 JP JP2021184620A patent/JP2022010260A/ja not_active Withdrawn
2022
- 2022-10-31 AU AU2022263460A patent/AU2022263460B2/en active Active
2023
- 2023-07-14 US US18/222,011 patent/US20240058342A1/en active Pending
2024
- 2024-05-15 JP JP2024079330A patent/JP2024098001A/ja active Pending
- 2024-09-17 AU AU2024219813A patent/AU2024219813A1/en active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11951112B2 (en)	2021-04-12	2024-04-09	Maxim Masiutin	Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

Also Published As

Publication number	Publication date
AU2020207774A1 (en)	2020-08-06
HUE068315T2 (hu)	2024-12-28
FI3096756T3 (fi)	2024-08-14
US20190231781A1 (en)	2019-08-01
DK3096756T3 (da)	2024-08-05
IL304134B1 (en)	2024-12-01
AU2015209452B2 (en)	2020-05-07
AU2015209452C1 (en)	2020-11-05
KR20210064407A (ko)	2021-06-02
MX389004B (es)	2025-03-20
IL246783A0 (en)	2016-08-31
IL317035A (en)	2025-01-01
SMT202400361T1 (it)	2024-11-15
BR112016016975A2 (pt)	2017-08-08
MX2022000080A (es)	2022-02-03
US20170020877A1 (en)	2017-01-26
JP6936825B2 (ja)	2021-09-22
SI3096756T1 (sl)	2024-09-30
US20210137926A1 (en)	2021-05-13
RU2016133972A3 (2)	2018-09-26
IL246783B (en)	2021-10-31
PL3096756T3 (pl)	2024-10-28
US10905690B2 (en)	2021-02-02
MX2021012539A (es)	2021-11-12
RU2718918C2 (ru)	2020-04-15
ES2984706T3 (es)	2024-10-30
CA3155599A1 (en)	2015-07-30
PT3096756T (pt)	2024-08-26
US20210361659A1 (en)	2021-11-25
US11311544B2 (en)	2022-04-26
IL296683B2 (en)	2023-12-01
IL296683B1 (en)	2023-08-01
MX2016009499A (es)	2017-02-27
JP2022010260A (ja)	2022-01-14
JP2024098001A (ja)	2024-07-19
IL286782A (en)	2021-10-31
LT3096756T (lt)	2024-08-26
RU2016133972A (ru)	2018-03-05
US11730739B2 (en)	2023-08-22
EP3096756B1 (en)	2024-06-12
JP2020138978A (ja)	2020-09-03
EP4450070A1 (en)	2024-10-23
AU2022263460B2 (en)	2024-10-17
AU2024219813A1 (en)	2024-10-10
IL304134B2 (en)	2025-04-01
JP6585625B2 (ja)	2019-10-02
US20240058342A1 (en)	2024-02-22
BR112016016975B1 (pt)	2022-12-27
KR20160106176A (ko)	2016-09-09
JP2017503030A (ja)	2017-01-26
EP3096756A1 (en)	2016-11-30
IL304134A (en)	2023-09-01
HRP20241046T1 (hr)	2024-11-08
RU2020112197A (ru)	2020-05-21
WO2015112642A1 (en)	2015-07-30
IL296683A (en)	2022-11-01
KR102258522B1 (ko)	2021-05-31
JP2019081814A (ja)	2019-05-30
JP7104743B2 (ja)	2022-07-21
AU2022263460A1 (en)	2022-12-08
AU2020207774B2 (en)	2022-08-04
CA2936974A1 (en)	2015-07-30
CN106102740A (zh)	2016-11-09
CN111228274A (zh)	2020-06-05
RS65839B1 (sr)	2024-09-30
AU2015209452A1 (en)	2016-08-04

Legal Events

Date	Code	Title	Description
2020-10-30	PSEA	Patent sealed
2021-01-29	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201231
2022-01-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20211230
2023-01-27	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20221230
2024-01-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2025 BY COMPUTER PACKAGES INC Effective date: 20231230
2025-01-31	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2026 BY COMPUTER PACKAGES INC Effective date: 20241230

Publication	Publication Date	Title
NZ722122A (en)	2020-06-26	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
IL290905B1 (en)	2023-05-01	Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MX2023004037A (es)	2023-04-27	Compuestos biciclicos como inhibidores alostericos de shp2.
MX384627B (es)	2025-03-14	Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxifenil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma
PE20120534A1 (es)	2012-05-10	PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
NZ711540A (en)	2018-08-31	Fused heterocyclic compounds as protein kinase inhibitors
WO2011149950A3 (en)	2012-04-12	Bicyclic heteroaryl kinase inhibitors and methods of use
EA201492176A1 (ru)	2015-08-31	Селективные ингибиторы pi3k дельта
MA44610A (fr)	2019-02-13	Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
HRP20210543T1 (hr)	2021-05-14	Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
JP2017503030A5 (2)	2018-03-01
PH12014500794A1 (en)	2014-10-20	Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PH12017500161B1 (en)	2022-05-18	6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PH12017500170A1 (en)	2017-07-10	6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
EA201691934A1 (ru)	2017-01-30	Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
MX2017001453A (es)	2017-05-11	Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).
MX2018014185A (es)	2019-02-25	Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
PH12016502540B1 (en)	2022-07-20	Pharmaceutical dosage forms
MX369840B (es)	2019-11-22	Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona.
EP3886891C0 (en)	2024-11-20	LAMININ RECEPTOR PRECURSOR/ HIGH AFFINITY LAMININ RECEPTOR (LRP/LR) FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
UA96476U (uk)	2015-02-10	ЗАСТОСУВАННЯ 7-(3-ГІДРОКСИФЕНІЛ)-6-КАРБЕТОКСИ-5-МЕТИЛ-4,7-ДИГІДРО[1,2,4]ТРИАЗОЛО-[1,5-a]ПІРИМІДИНУ ДЛЯ КОРЕКЦІЇ ПОРУШЕНЬ СТРУКТУРИ КІСТКОВОЇ ТКАНИНИ ПРИ ГІПОТИРЕОЇДНИХ СТАНАХ
MX2016007494A (es)	2016-10-03	Tratamiento de la esclerosis multiple con un derivado de 1,2,4-triazolo [1,5-a] piridina.

NZ722122A - Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=52450623

Family Applications (1)

Country Status (24)

Cited By (1)

Families Citing this family (12)

Family Cites Families (67)

Cited By (1)

Also Published As

Similar Documents

Legal Events